ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - leuprorelin acetate 11.25 mg - powder for suspension for injection - leuprorelin - endometriosis prostatic cancer treatment of uterine fibroids for a period of up to six months. treatment of breast cancer in pre- and peri - menopausal women in whom hormone therapy is specified.

ישראל - עברית - Ministry of Health

ferring pharmaceuticals ltd - triptorelin as acetate - powder for suspension for injection - triptorelin as acetate 3.75 mg/vial - triptorelin - triptorelin - lowering sexual hormones, prostate cancer, endomedtriosis, uterus myomatosus, fertility treatment ivf. central precocious puberty.

ישראל - עברית - Ministry of Health

takeda israel ltd - mifamurtide - powder for suspension for infusion - mifamurtide 4 mg/vial - mifamurtide - mifamurtide - mepact is indicated in children, adolescents and young adults for the treatment of high grade resectable non metastatic osteosarcoma after macroscopically complete surgical resection. it is used in combination with post operative multi-agent chemotherapy. safety and efficacy have been assessed in studies of patients 2 to 30 years of age at initial diagnosis.

ישראל - עברית - Ministry of Health

mediline ltd. - strontium ranelate 2 g - granules for oral suspension - strontium ranelate - treatment of postmenopausal osteoporosis to reduce the risk of vertebral and hip fractures.

ישראל - עברית - Ministry of Health

eli lilly israel ltd - olanzapine 210 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

ישראל - עברית - Ministry of Health

eli lilly israel ltd - olanzapine 300 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

ישראל - עברית - Ministry of Health

eli lilly israel ltd - olanzapine as pamoate monohydrate 405 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

ישראל - עברית - Ministry of Health

lapidot medical import and marketing ltd - betaxolol hydrochloride 2.8 mg/ml - ophthalmic suspension - betaxolol - selective beta blocker. to lower the intraocular pressure.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - calcium 30 mg / 100 g; chloride 223 mg / 100 g - powder for suspension - calcium - for dietary caloric support.

ישראל - עברית - Ministry of Health

abbott medical laboratories ltd - artificial butterscotch flavor 146 mg / 100 g; artificial vanilla 1.9 g / 100 g - powder for suspension - fat/carbohydrates/proteins/minerals/vitamins, combinations - specialized elemental nutrition with glutamine for metabolically stressed patients with gastrointestinal complications.may be used as a sole source of nutrition or as a supplement to a prescribed diet.